Octapharma’s Wilate Product Now Available

Octapharma USA May 13 announced that Wilate, the first replacement therapy for the treatment of the bleeding disorder von Willebrand Disease (VWD), now is available from the company’s authorized distributors.

The Food and Drug Administration approved Wilate for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe VWD as well as in patients with mild or moderate forms of the illness who cannot take desmopressin, the Hoboken, N.J.-based company said.

Octapharma USA is the U.S. division of Octapharma AG, a Swiss-based manufacturer of plasma products.